RIPK1 Inhibitor Ameliorates Pulmonary Injury by Modulating the Function of Neutrophils and Vascular Endothelial Cells

Investigators explored the pathological role of RIPK1 in acute lung injury, especially in the pulmonary immune microenvironment involving neutrophils and endothelial cells. In vivo experiments showed that RIPK1 inhibitor protected against lipopolysaccharide-induced lung injury in mouse models, with reduced neutrophils and monocytes infiltration in the lungs.